MedTrace Logo

Investigation of the Relationship Between Peripheral and Central Metabolic Changes Induced by GLP-1 Agonists

NCT06818292 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-02-10

No results posted yet for this study

Summary

This study aims to investigate the acute effects of Liraglutide, a GLP-1 receptor agonist established in the treatment of type 2 diabetes and obesity, on brain metabolism, brain network function, and executive functioning as well as mood in healthy, normal-weight individuals. Given the emerging evidence of GLP-1's impact on brain function, including the modulation of reward processing and cognitive functions, this study will focus on the physiological changes induced by Liraglutide and their potential implications for brain health. The overall goal of this study is to assess how acute GLP-1 administration influences systemic and brain metabolism to modulate brain signalling and behaviour.

Conditions

  • Healthy

Interventions

BIOLOGICAL

Liraglutide

0.6 mg of the pre-filled solutions from pen-injector Liraglutide (GLP-1 Agonist)

BIOLOGICAL

Placebo

0.1 mL NaCl

Sponsors & Collaborators

  • University Hospital, Bonn

    collaborator OTHER

  • Johann Wolfgang Goethe University Hospital

    collaborator OTHER

  • Nils Opel

    lead OTHER

Principal Investigators

  • Sharmili Edwin Thanarajah, PD Dr med · Goethe University

  • Nils Gassen, Prof Dr · University Hospital, Bonn

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
43 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-10-21
Primary Completion
2024-12-06
Completion
2024-12-06

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06818292 on ClinicalTrials.gov